Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Mylan Inc has confirmed that the company and its subsidiary, Mylan Pharmaceuticals Inc have been sued by Novartis in connection with fluvastatin capsules USP, 20mg and 40mg, the generic version of Novartis's Lescol capsules.
Subscribe to our email newsletter
Mylan believes that it is the first company to file a substantially complete abbreviated new drug application (ANDA) containing a paragraph IV certification for the product.
The company has filed an ANDA with the FDA in June 2008. Novartis has filed a lawsuit in the US District Court of New Jersey alleging infringement of US patent.
Fluvastatin capsules are used in the treatment of high cholesterol. Currently, Mylan has 108 ANDAs pending FDA approval, 22 of which are potential first-to-file opportunities.